Barclays PLC Has $121,000 Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Barclays PLC grew its holdings in Fractyl Health, Inc. (NASDAQ:GUTS) by 1,754.7% during the third quarter, Holdings Channel reports. The firm owned 47,796 shares of the company’s stock after acquiring an additional 45,219 shares during the quarter. Barclays PLC’s holdings in Fractyl Health were worth $121,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Fractyl Health in the 3rd quarter valued at about $51,000. Jane Street Group LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at about $25,000. State Street Corp lifted its stake in shares of Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after purchasing an additional 63,968 shares during the period. HighTower Advisors LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at about $38,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the period.

Fractyl Health Stock Down 5.9 %

Shares of NASDAQ:GUTS opened at $1.90 on Thursday. The company has a market capitalization of $91.39 million and a price-to-earnings ratio of -0.16. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The business’s 50-day moving average is $2.21 and its 200-day moving average is $2.83. Fractyl Health, Inc. has a 1 year low of $1.74 and a 1 year high of $14.50.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. Equities research analysts predict that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Harith Rajagopalan sold 96,517 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. This represents a 16.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $158,566.59. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.